Here comes Humira competition
MGA’s analysis of the competition as new adalimumab biosimilars enter market.
Alex Brill Interviewed on the Future of the Adalimumab Market
MGA’s Alex Brill was interviewed by Mari Serebvrov for a new piece in BioWorld to discuss the latest with the adalimumab market as new competition is expected as early as July 1.
A More Affordable Future Through Competition
“If Republicans take control of Congress in this fall’s election, protecting previously passed policies will be among the party’s top priority, said Alex Brill, a senior fellow at the American Enterprise Institute for Public Policy Research, a conservative think tank based in Washington, D.C. “
MGA Report Cited in Forbes Article on Rising Prescription Drug Prices
In his Forbes article, Ike Brannon discusses the blame game being played in Washington in regards to skyrocketing drug prices. MGA’s report “Understanding Drug Rebates and Their Role in Promoting Competition” was utilized by Brannon to bolster the argument that it is the drug companies who are responsible for drug pricing.
IAM Quotes MGA Report in Article Discussing the Problem of Patent Thickets
In his article for Intellectual Asset Management (IAM), Life Sciences Reporter Adam Houldsworth discusses the weaknesses in the US patent system that enable the “thorny” problem of patent thickets. MGA’s report, “How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing,” was featured heavily in the article to provide evidence of the growing problem.
Alex Brill Interviewed on Future of US Biosimilars Market
In a new BioWorld article, Mari Serebrov discusses efforts by Congress to control US prescription drug prices. Interviewed for the article was MGA’s Alex Brill, who talks about the potential side effects of such efforts.
- Patent Thicket Remedies
- Don’t Mix US Tax Administration Policy with the Israel-Hamas Conflict
- The Economics of “Delinking” PBM Compensation
- The Supreme Court Should Leave the Tax Code Alone
- Implications of Cannabis Legalization for the US Federal Budget
- Amicus Brief in Moore v. United States
- Biosimilars – Keys to Success in the Pharmacy Benefit
- New MGA White Paper Examines Consequences of Regulatory Uncertainty for Employee Ownership
- MGA Releases White Paper on Role of PBMs in US Drug Pricing Debate
- Unintended Consequences of Limiting PBMs
